C Anquetil1, S Abdelhamid2, A Gelis3, C Fattal4. 1. CHRU Lapeyronie, Service MPR, Montpellier, France. 2. Clinique Beausoleil, Service d'Urologie, Montpellier, France. 3. Rehab Centre CMN Propara, Montpellier, France. 4. Rehab Centre COS DIVIO, Dijon, France.
Abstract
STUDY DESIGN: Cross-sectional study. OBJECTIVES: To compare quality of life (QoL) in patients with spinal cord injury (SCI) who underwent overactive detrusor treatment by botulinum toxin (BT) versus augmentation cystoplasty (AC). SETTING: France. METHODS: Prospective and descriptive study: Patients with a refractory overactive bladder due to SCI treated by at least two successive injections of BT or by AC. QoL was assessed using Qualiveen-30 (Q30). Clinical data and urodynamic parameters were collected. RESULTS: Thirty patients were included between March 2013 and March 2014: 14 in arm 1 (BT injections) and 16 in arm 2 (AC). Mean postoperative time after AC was 9.94 years. Mean BT injections already performed was 6.36. Qol was significantly lower in arm 1-Q30 score 1.625 versus arm 2-Q30 score 1.077 (P=0.037). Continence control was significantly higher in arm 2. Fourteen patients were completely continent (87.5%) in arm 2, whereas only 6 (42.3%) were continent in arm 1 (P=0.0187). Urinary infection, reflux, diverticula and stones were almost at a similar occurrence level. CONCLUSIONS: QoL was found to be higher with an AC compared with BT injections. Long-time intervals between two injections and advantages specific to AC might explain in part these findings.
STUDY DESIGN: Cross-sectional study. OBJECTIVES: To compare quality of life (QoL) in patients with spinal cord injury (SCI) who underwent overactive detrusor treatment by botulinum toxin (BT) versus augmentation cystoplasty (AC). SETTING: France. METHODS: Prospective and descriptive study: Patients with a refractory overactive bladder due to SCI treated by at least two successive injections of BT or by AC. QoL was assessed using Qualiveen-30 (Q30). Clinical data and urodynamic parameters were collected. RESULTS: Thirty patients were included between March 2013 and March 2014: 14 in arm 1 (BT injections) and 16 in arm 2 (AC). Mean postoperative time after AC was 9.94 years. Mean BT injections already performed was 6.36. Qol was significantly lower in arm 1-Q30 score 1.625 versus arm 2-Q30 score 1.077 (P=0.037). Continence control was significantly higher in arm 2. Fourteen patients were completely continent (87.5%) in arm 2, whereas only 6 (42.3%) were continent in arm 1 (P=0.0187). Urinary infection, reflux, diverticula and stones were almost at a similar occurrence level. CONCLUSIONS: QoL was found to be higher with an AC compared with BT injections. Long-time intervals between two injections and advantages specific to AC might explain in part these findings.
Authors: François Haab; Gérard Amarenco; Patrick Coloby; Philippe Grise; Bernard Jacquetin; Jean-Jacques Labat; Emmanuel Chartier-Kastler; François Richard Journal: Prog Urol Date: 2004-12 Impact factor: 0.915
Authors: Priya Padmanabhan; Harriette M Scarpero; Douglas F Milam; Roger R Dmochowski; David F Penson Journal: World J Urol Date: 2010-11-26 Impact factor: 4.226
Authors: P Costa; B Perrouin-Verbe; A Colvez; J Didier; P Marquis; A Marrel; G Amarenco; B Espirac; A Leriche Journal: Eur Urol Date: 2001-01 Impact factor: 20.096
Authors: Jairam R Eswara; Miguel Castellan; Ricardo González; Nicolas Mendieta; Marc Cendron Journal: World J Urol Date: 2018-08-13 Impact factor: 4.226